- Home
- INVA
INVA
Innoviva Inc.
as 07-26-2024 4:00pm EST
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | 1.1B | IPO Year: | 2004 |
| Target Price: | N/A | AVG Volume (30 days): | 527.2K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.21 | EPS Growth: | -14.01 |
| 52 Week Low/High: | $12.22 - $18.64 | Next Earning Date: | 08-05-2024 |
| Revenue: | $311,590,000 | Revenue Growth: | -1.91% |
| Revenue Growth (this year): | 1.03% | Revenue Growth (next year): | 8.68% |
Stock Insider Trading Activity of Innoviva Inc. (INVA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zhen Marianne | INVA | Chief Accounting Officer | Nov 15 '23 | Sell | $14.01 | 5,589 | $78,301.89 | 45,563 | SEC Form 4 |
| Zhen Marianne | INVA | Chief Accounting Officer | Nov 15 '23 | Sell | $13.97 | 5,405 | $75,507.85 | 40,158 | SEC Form 4 |
Latest Innoviva Inc. News
INVA Breaking Stock News: Dive into INVA Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
INVA: Raising target price to $19.00
Simply Wall St.
10 days ago
Innoviva (NASDAQ:INVA) shareholders have earned a 36% return over the last year
Argus Research
10 days ago
INVA: Raising target price to $18.00
Argus Research
17 days ago
INVA: What does Argus have to say about INVA?
The Fly
a month ago
Apple downgraded, Kroger upgraded: Wall Street's top analyst calls
Simply Wall St.
2 months ago
Calculating The Fair Value Of Innoviva, Inc. (NASDAQ:INVA)
Business Wire
2 months ago
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
MT Newswires
2 months ago
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
Compare INVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INVA Innoviva Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.